Alabama Entrepreneurship Institute pilot accelerator graduate City Detect secures $2M in seed round funding (Theresa M. Welbourne for the Birmingham Business Journal)
City Detect, which participated in the Alabama Entrepreneurship Institute’s 2023 pilot Crimson Accelerator program, secured a $2M seed funding round led by Las Olas Venture Capital.
California company relocates, says Bham is “what we were looking for” (Harper Harwell for the Birmingham Business Journal)
Tamar Blue, the founder of the mental health startup MentalHappy, discusses her decision to move the company from Silicon Valley to Birmingham.
From Birmingham to the White House: Embracing AI’s potential for innovators (Del Smith for the Birmingham Business Journal)
Del Smith of Acclinate, a startup dedicated to increasing diversity in clinical trials, discusses how AI regulations could affect innovation and small businesses.
Local e-learning company shifting focus with AI software launch (Harper Harwell for the Birmingham Business Journal)
CAVU, a business coaching e-learning platform, introduces a new AI-native Application Lifecycle Management (ALM) system, Rhythmic, to simplify planning and improve productivity.
MotionMobs founders launch new fintech startup (Harper Harwell for the Birmingham Business Journal)
The founders of MotionMobs, a software development company, have created a new startup, Occupi, that helps streamline the rental process for landlords and renters.
Prominent Birmingham executive leaving CEO post ( Stephanie Rebman for the Birmingham Business Journal)
Southern Research CEO Josh Carpenter announces that he’s stepping down from the position he’s held since May of 2021.
Startup partnering with Hardware Park to develop medical prototype (Harper Harwell for the Birmingham Business Journal)
NephSol partners with Hardware Park’s Fall NextGen Student Cohort to develop a blood flow monitor for use during dialysis.
UAB startup receives FDA approval for diabetes drug (Harper Harwell for the Birmingham Business Journal)
Birmingham-based startup TIXiMED has received IND approval from the FDA for its novel oral antidiabetic, TIX100, which may become the first oral, non-immunosuppressive treatment for people with type 1 diabetes.